UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Presentations
Can lay health workers achieve the triple aim? Results from the
Engagement of Patients with Advanced Cancer (EPAC) trial.
Authors*: Manali I. Patel, VJ Periyakoil, Kate Bundorf, David Thom, Arnold Milstein, Steven M Asch, James Kahn
Abstract #: 6507
Presentation Date/Time: Monday, June 6: 9:45 AM - 12:45 PM
Location: S100a
Session: Health Services Research and Quality of Care
Citation: J Clin Oncol 34, 2016 (suppl; abstr 6507)
__________________________________________________________________________
Phase I investigation of lenalidomide plus rituximab and outcomes of
lenalidomide maintenance in recurrent CNS lymphoma.
Authors*: James L. Rubenstein, Eleanor Fraser, Paul Formaker, James Chi-Chiang Lee, Nianhang Chen,
Mallory Kock, Wesley Cheung, Xiaomin Wang, Pamela N. Munster, Bertil Damato
Abstract #: 7502
Presentation Date/Time: Sunday, June 5: 9:45 AM - 12:45 PM
Location: E354b
Oral Abstract Session: Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia
Citation: J Clin Oncol 34, 2016 (suppl; abstr 7502)
Rubenstein Research Interests: Our goals are to develop innovative therapies that are based upon the
biological properties of cancer, that have both enhanced efficacy as well as less toxicity compared to
established interventions. Our major interests are: 1) identification of genetic factors associated with
therapeutic resistance; 2) molecular basis of tumor cell tropism within the brain; 3) elucidation of the tumor
immune microenvironment. We are simultaneously engaged in leading phase I and II trials , in correlative
studies involving novel immunotherapeutic strategies, in the development of novel preclinical models that
facilitate both insights into disease mechanisms as well as the testing of novel therapeutic strategies.
https://bms.ucsf.edu/directory/faculty/james-rubenstein-md-phd
*UCSF authors in bold
73